A randomized, double‐blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine‐induced cutaneous responses in healthy adult volunteers
Background: Cetirizine is a highly efficacious and long‐acting second‐generation H1‐receptor antagonist for the treatment of allergic diseases, such as allergic rhinitis and chronic idiopathic urticaria, in adults and children. Pharmacologic studies have demonstrated that cetirizine, a racemate mixt...
Saved in:
| Published in | Allergy (Copenhagen) Vol. 56; no. 1; pp. 50 - 57 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Copenhagen
Munksgaard International Publishers
01.01.2001
Blackwell |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background: Cetirizine is a highly efficacious and long‐acting second‐generation H1‐receptor antagonist for the treatment of allergic diseases, such as allergic rhinitis and chronic idiopathic urticaria, in adults and children. Pharmacologic studies have demonstrated that cetirizine, a racemate mixture composed of equal amounts of two enantiomers, does not undergo hepatic metabolism to any significant level. The enantiomers are excreted mainly unchanged, predominantly in the urine and to a lesser extent in the faeces.
Methods: The pharmacologic activity and potency of the two enantiomers of cetirizine in the management of allergic skin conditions were investigated by studying the effect of treatment with 5.0 mg cetirizine; 2.5 mg levocetirizine, the (R)‐enantiomer; and 2.5 mg ucb 28557, the (S)‐enantiomer, on histamine‐induced wheal and flare response in 18 healthy volunteers. Each treatment was administered as a single oral dose in randomized, double‐blind, and crossover manner, and the efficacy of treatment was assessed over a period of 32 h, as per cent inhibition of the histamine‐induced wheal and flare areas before treatment. Blood and urine samples were collected in a time‐dependent manner and analyzed for the total amounts of each study drug, to elucidate their pharmacokinetic profiles.
Results: Both cetirizine and levocetirizine caused a marked inhibition of histamine‐induced wheal and flare, whereas ucb 28557 was inactive in this model. Inhibition of the wheal response observed for cetirizine and levocetirizine was apparent by 1 h after dosage and lasted for mean durations of 24.4 and 28.4 h, respectively. In addition, the response for cetirizine and levocetirizine became maximal by 6 h after treatment, rising to 79.5% and 83.8%. Similarly, cetirizine and levocetirizine also markedly inhibited the histamine‐induced flare response. This effect was evident for both drugs by 1 h after dosage and lasted over a mean period of 28.4 and 26.0 h, respectively, for cetirizine and levocetirizine. The inhibitory effect of these compounds on histamine‐induced flare response was also maximal by approximately 6 h after dosage, peaking at 88.5% and 83.6%, respectively. Statistical evaluation showed that cetirizine and levocetirizine were equivalent for maximum inhibition of histamine‐induced wheal and flare. However, levocetirizine was found to be superior to cetirizine when area under the curve was compared. In contrast, ucb 28557 was not found to inhibit histamine‐induced wheal and flare responses at any time during the study period. Plasma concentrations of levocetirizine were found to be approximately double those of ucb 28557 at 4 and 8 h after dosing, and 50–60% of the drugs were excreted unchanged in urine over a period of 32 h.
Conclusions: The finding that, in this model, levocetirizine 2.5 mg has comparable antihistaminic activity to cetirizine 5 mg, whereas its other enantiomer ucb 28557 has no pharmacodynamic effect, suggests that the antihistaminic properties of cetirizine observed in the management of allergic skin conditions are likely to be attributable to levocetirizine. |
|---|---|
| AbstractList | Cetirizine is a highly efficacious and long-acting second-generation H sub(1)-receptor antagonist for the treatment of allergic diseases, such as allergic rhinitis and chronic idiopathic urticaria, in adults and children. Pharmacologic studies have demonstrated that cetirizine, a racemate mixture composed of equal amounts of two enantiomers, does not undergo hepatic metabolism to any significant level. The enantiomers are excreted mainly unchanged, predominantly in the urine and to a lesser extent in the faeces. The pharmacologic activity and potency of the two enantiomers of cetirizine in the management of allergic skin conditions were investigated by studying the effect of treatment with 5.0 mg cetirizine; 2.5 mg levocetirizine, the (R)-enantiomer; and 2.5 mg ucb 28557, the (S)-enantiomer, on histamine-induced wheal and flare response in 18 healthy volunteers. Each treatment was administered as a single oral dose in randomized, double-blind, and crossover manner, and the efficacy of treatment was assessed over a period of 32 h, as per cent inhibition of the histamine-induced wheal and flare areas before treatment. Blood and urine samples were collected in a time-dependent manner and analyzed for the total amounts of each study drug, to elucidate their pharmacokinetic profiles. Both cetirizine and levocetirizine caused a marked inhibition of histamine-induced wheal and flare, whereas ucb 28557 was inactive in this model. Inhibition of the wheal response observed for cetirizine and levocetirizine was apparent by 1 h after dosage and lasted for mean durations of 24.4 and 28.4 h, respectively. In addition, the response for cetirizine and levocetirizine became maximal by 6 h after treatment, rising to 79.5% and 83.8%. Similarly, cetirizine and levocetirizine also markedly inhibited the histamine-induced flare response. This effect was evident for both drugs by 1 h after dosage and lasted over a mean period of 28.4 and 26.0 h, respectively, for cetirizine and levocetirizine. The inhibitory effect of these compounds on histamine-induced flare response was also maximal by approximately 6 h after dosage, peaking at 88.5% and 83.6%, respectively. Statistical evaluation showed that cetirizine and levocetirizine were equivalent for maximum inhibition of histamine-induced wheal and flare. However, levocetirizine was found to be superior to cetirizine when area under the curve was compared. In contrast, ucb 28557 was not found to inhibit histamine-induced wheal and flare responses at any time during the study period. Plasma concentrations of levocetirizine were found to be approximately double those of ucb 28557 at 4 and 8 h after dosing, and 50-60% of the drugs were excreted unchanged in urine over a period of 32 h. The finding that, in this model, levocetirizine 2.5 mg has comparable antihistaminic activity to cetirizine 5 mg, whereas its other enantiomer ucb 28557 has no pharmacodynamic effect, suggests that the antihistaminic properties of cetirizine observed in the management of allergic skin conditions are likely to be attributable to levocetirizine. Cetirizine is a highly efficacious and long-acting second-generation H1-receptor antagonist for the treatment of allergic diseases, such as allergic rhinitis and chronic idiopathic urticaria, in adults and children. Pharmacologic studies have demonstrated that cetirizine, a racemate mixture composed of equal amounts of two enantiomers, does not undergo hepatic metabolism to any significant level. The enantiomers are excreted mainly unchanged, predominantly in the urine and to a lesser extent in the faeces. The pharmacologic activity and potency of the two enantiomers of cetirizine in the management of allergic skin conditions were investigated by studying the effect of treatment with 5.0 mg cetirizine; 2.5 mg levocetirizine, the (R)-enantiomer; and 2.5 mg ucb 28557, the (S)-enantiomer, on histamine-induced wheal and flare response in 18 healthy volunteers. Each treatment was administered as a single oral dose in randomized, double-blind, and crossover manner, and the efficacy of treatment was assessed over a period of 32 h, as per cent inhibition of the histamine-induced wheal and flare areas before treatment. Blood and urine samples were collected in a time-dependent manner and analyzed for the total amounts of each study drug, to elucidate their pharmacokinetic profiles. Both cetirizine and levocetirizine caused a marked inhibition of histamine-induced wheal and flare, whereas ucb 28557 was inactive in this model. Inhibition of the wheal response observed for cetirizine and levocetirizine was apparent by 1 h after dosage and lasted for mean durations of 24.4 and 28.4 h, respectively. In addition, the response for cetirizine and levocetirizine became maximal by 6 h after treatment, rising to 79.5% and 83.8%. Similarly, cetirizine and levocetirizine also markedly inhibited the histamine-induced flare response. This effect was evident for both drugs by 1 h after dosage and lasted over a mean period of 28.4 and 26.0 h, respectively, for cetirizine and levocetirizine. The inhibitory effect of these compounds on histamine-induced flare response was also maximal by approximately 6 h after dosage, peaking at 88.5%) and 83.6%, respectively. Statistical evaluation showed that cetirizine and levocetirizine were equivalent for maximum inhibition of histamine-induced wheal and flare. However, levocetirizine was found to be superior to cetirizine when area under the curve was compared. In contrast, ucb 28557 was not found to inhibit histamine-induced wheal and flare responses at any time during the study period. Plasma concentrations of levocetirizine were found to be approximately double those of ucb 28557 at 4 and 8 h after dosing, and 50-60% of the drugs were excreted unchanged in urine over a period of 32 h. The finding that, in this model, levocetirizine 2.5 mg has comparable antihistaminic activity to cetirizine 5 mg, whereas its other enantiomer ucb 28557 has no pharmacodynamic effect, suggests that the antihistaminic properties of cetirizine observed in the management of allergic skin conditions are likely to be attributable to levocetirizine. Background: Cetirizine is a highly efficacious and long‐acting second‐generation H1‐receptor antagonist for the treatment of allergic diseases, such as allergic rhinitis and chronic idiopathic urticaria, in adults and children. Pharmacologic studies have demonstrated that cetirizine, a racemate mixture composed of equal amounts of two enantiomers, does not undergo hepatic metabolism to any significant level. The enantiomers are excreted mainly unchanged, predominantly in the urine and to a lesser extent in the faeces. Methods: The pharmacologic activity and potency of the two enantiomers of cetirizine in the management of allergic skin conditions were investigated by studying the effect of treatment with 5.0 mg cetirizine; 2.5 mg levocetirizine, the (R)‐enantiomer; and 2.5 mg ucb 28557, the (S)‐enantiomer, on histamine‐induced wheal and flare response in 18 healthy volunteers. Each treatment was administered as a single oral dose in randomized, double‐blind, and crossover manner, and the efficacy of treatment was assessed over a period of 32 h, as per cent inhibition of the histamine‐induced wheal and flare areas before treatment. Blood and urine samples were collected in a time‐dependent manner and analyzed for the total amounts of each study drug, to elucidate their pharmacokinetic profiles. Results: Both cetirizine and levocetirizine caused a marked inhibition of histamine‐induced wheal and flare, whereas ucb 28557 was inactive in this model. Inhibition of the wheal response observed for cetirizine and levocetirizine was apparent by 1 h after dosage and lasted for mean durations of 24.4 and 28.4 h, respectively. In addition, the response for cetirizine and levocetirizine became maximal by 6 h after treatment, rising to 79.5% and 83.8%. Similarly, cetirizine and levocetirizine also markedly inhibited the histamine‐induced flare response. This effect was evident for both drugs by 1 h after dosage and lasted over a mean period of 28.4 and 26.0 h, respectively, for cetirizine and levocetirizine. The inhibitory effect of these compounds on histamine‐induced flare response was also maximal by approximately 6 h after dosage, peaking at 88.5% and 83.6%, respectively. Statistical evaluation showed that cetirizine and levocetirizine were equivalent for maximum inhibition of histamine‐induced wheal and flare. However, levocetirizine was found to be superior to cetirizine when area under the curve was compared. In contrast, ucb 28557 was not found to inhibit histamine‐induced wheal and flare responses at any time during the study period. Plasma concentrations of levocetirizine were found to be approximately double those of ucb 28557 at 4 and 8 h after dosing, and 50–60% of the drugs were excreted unchanged in urine over a period of 32 h. Conclusions: The finding that, in this model, levocetirizine 2.5 mg has comparable antihistaminic activity to cetirizine 5 mg, whereas its other enantiomer ucb 28557 has no pharmacodynamic effect, suggests that the antihistaminic properties of cetirizine observed in the management of allergic skin conditions are likely to be attributable to levocetirizine. Background: Cetirizine is a highly efficacious and long‐acting second‐generation H 1 ‐receptor antagonist for the treatment of allergic diseases, such as allergic rhinitis and chronic idiopathic urticaria, in adults and children. Pharmacologic studies have demonstrated that cetirizine, a racemate mixture composed of equal amounts of two enantiomers, does not undergo hepatic metabolism to any significant level. The enantiomers are excreted mainly unchanged, predominantly in the urine and to a lesser extent in the faeces. Methods: The pharmacologic activity and potency of the two enantiomers of cetirizine in the management of allergic skin conditions were investigated by studying the effect of treatment with 5.0 mg cetirizine; 2.5 mg levocetirizine, the ( R )‐enantiomer; and 2.5 mg ucb 28557, the ( S )‐enantiomer, on histamine‐induced wheal and flare response in 18 healthy volunteers. Each treatment was administered as a single oral dose in randomized, double‐blind, and crossover manner, and the efficacy of treatment was assessed over a period of 32 h, as per cent inhibition of the histamine‐induced wheal and flare areas before treatment. Blood and urine samples were collected in a time‐dependent manner and analyzed for the total amounts of each study drug, to elucidate their pharmacokinetic profiles. Results: Both cetirizine and levocetirizine caused a marked inhibition of histamine‐induced wheal and flare, whereas ucb 28557 was inactive in this model. Inhibition of the wheal response observed for cetirizine and levocetirizine was apparent by 1 h after dosage and lasted for mean durations of 24.4 and 28.4 h, respectively. In addition, the response for cetirizine and levocetirizine became maximal by 6 h after treatment, rising to 79.5% and 83.8%. Similarly, cetirizine and levocetirizine also markedly inhibited the histamine‐induced flare response. This effect was evident for both drugs by 1 h after dosage and lasted over a mean period of 28.4 and 26.0 h, respectively, for cetirizine and levocetirizine. The inhibitory effect of these compounds on histamine‐induced flare response was also maximal by approximately 6 h after dosage, peaking at 88.5% and 83.6%, respectively. Statistical evaluation showed that cetirizine and levocetirizine were equivalent for maximum inhibition of histamine‐induced wheal and flare. However, levocetirizine was found to be superior to cetirizine when area under the curve was compared. In contrast, ucb 28557 was not found to inhibit histamine‐induced wheal and flare responses at any time during the study period. Plasma concentrations of levocetirizine were found to be approximately double those of ucb 28557 at 4 and 8 h after dosing, and 50–60% of the drugs were excreted unchanged in urine over a period of 32 h. Conclusions: The finding that, in this model, levocetirizine 2.5 mg has comparable antihistaminic activity to cetirizine 5 mg, whereas its other enantiomer ucb 28557 has no pharmacodynamic effect, suggests that the antihistaminic properties of cetirizine observed in the management of allergic skin conditions are likely to be attributable to levocetirizine. |
| Author | De Vos, C. Baltes, E. Devalia, J. L. Hanotte, F. |
| Author_xml | – sequence: 1 givenname: J. L. surname: Devalia fullname: Devalia, J. L. – sequence: 2 givenname: F. surname: Hanotte fullname: Hanotte, F. – sequence: 3 givenname: E. surname: Baltes fullname: Baltes, E. – sequence: 4 givenname: C. surname: De Vos fullname: De Vos, C. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=855627$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11167352$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUtuFDEQhi0URCaBKyBLSKzSjR_9ssRmFPGSRmIDa8ttVxOP3PZgd08yWXEErsG1OAnuzCiwZGVb9dVfVn0X6MwHDwhhSkpKePVmW1IuukIIUZeMEFoS0rKmvHuCVo-FM7QilNRFVfPuHF2ktCULJcgzdE4pbVpesxX6tcZReRNGew_mCpsw9w5-__jZO-vzW8eQUthDxDqMOxVtCh6rMfhvWMNko723Hq6wg334950T8ax7zLq6bnFuubFpUmOu5egcPGswWM-T8hDmhCOkXfAJErYZBeWmmwNWZnYT3gc3-wkgpufo6aBcghen8xJ9ff_uy_XHYvP5w6fr9abQVSeaQhvCoKYN7xlt9aCMUJBXQBSFtmUgQANXbU-7vuED8EEoPQhQTaMZ7Yfe8Ev0-pi7i-H7DGmSo00anDt-VtK2q2pRdRnsjuDDkiIMchftqOJBUiIXTXIrFxtysSEXTfJBk7zLrS9PM-Z-BPO38eQlA69OgEpauSE70jY9cnmtDWsz9fZI3VoHh_8eL9ebTb7wP4chtjE |
| CODEN | LLRGDY |
| CitedBy_id | crossref_primary_10_1517_13543784_11_2_259 crossref_primary_10_36691_RJA764 crossref_primary_10_36691_RJA1055 crossref_primary_10_1016_j_tetasy_2009_02_013 crossref_primary_10_1016_j_jaubas_2012_02_002 crossref_primary_10_1046_j_1365_2745_2002_01444_x crossref_primary_10_1016_j_xphs_2022_12_021 crossref_primary_10_1080_10242422_2019_1602611 crossref_primary_10_1046_j_1472_8206_2001_00035_x crossref_primary_10_1111_j_1365_2222_2007_02662_x crossref_primary_10_1016_j_intimp_2005_05_008 crossref_primary_10_1111_j_1365_2125_2005_02242_x crossref_primary_10_1016_j_anai_2011_08_012 crossref_primary_10_25208_vdv1050 crossref_primary_10_1046_j_1365_2125_2003_01897_x crossref_primary_10_1111_j_1365_2133_2006_07548_x crossref_primary_10_1039_D1OB00289A crossref_primary_10_1097_MNM_0b013e328013eb3f crossref_primary_10_1016_j_saa_2009_09_033 crossref_primary_10_1016_j_curtheres_2007_12_004 crossref_primary_10_1111_j_1399_3038_2008_00816_x crossref_primary_10_1007_s00228_007_0366_5 crossref_primary_10_1016_j_jaip_2020_08_055 crossref_primary_10_1002_chir_20400 crossref_primary_10_1016_S1081_1206_10_60396_1 crossref_primary_10_3109_21556660_2014_928302 crossref_primary_10_1016_j_saa_2022_122098 crossref_primary_10_1111_j_1365_2222_2004_01960_x crossref_primary_10_1111_j_1368_5031_2005_00521_x crossref_primary_10_2165_00003495_200565030_00004 crossref_primary_10_1097_WOX_0b013e318214ba84 crossref_primary_10_1517_14740338_1_3_225 crossref_primary_10_1002_ejoc_201000113 crossref_primary_10_1186_1939_4551_4_S3_S32 crossref_primary_10_1586_1744666X_1_4_495 crossref_primary_10_1021_jo5012653 crossref_primary_10_1034_j_1398_9995_2003_00171_x crossref_primary_10_1089_ped_2013_0285 crossref_primary_10_1124_dmd_105_007211 crossref_primary_10_1016_j_jaci_2004_01_773 crossref_primary_10_1016_S1081_1206_10_61208_2 crossref_primary_10_1186_1710_1492_5_14 crossref_primary_10_1002_tcr_202100209 crossref_primary_10_1016_j_ejphar_2014_07_021 crossref_primary_10_1517_14656566_9_5_859 crossref_primary_10_3109_08923973_2013_812653 crossref_primary_10_1016_S1081_1206_10_61995_3 crossref_primary_10_1159_000083795 crossref_primary_10_1159_000083796 crossref_primary_10_3103_S0027131412060089 crossref_primary_10_36691_RJA490 crossref_primary_10_2165_00044011_200828040_00003 crossref_primary_10_2165_00044011_200626010_00001 crossref_primary_10_1002_chir_21992 crossref_primary_10_36691_RJA284 crossref_primary_10_1517_14656566_5_7_1581 crossref_primary_10_1002_chem_201203946 crossref_primary_10_1007_BF03257160 crossref_primary_10_1080_00397911_2019_1710213 crossref_primary_10_1007_s00044_010_9512_1 crossref_primary_10_36691_RJA1125 crossref_primary_10_1080_10242422_2019_1568416 crossref_primary_10_1016_S0006_2952_03_00558_6 crossref_primary_10_1021_ol0627909 crossref_primary_10_1111_j_1365_2885_2007_00850_x crossref_primary_10_1034_j_1398_9995_2001_00204_x crossref_primary_10_1067_mai_2003_63 crossref_primary_10_1021_acs_orglett_9b01056 crossref_primary_10_1021_jacs_8b08640 crossref_primary_10_1002_jhet_3681 crossref_primary_10_1007_s40265_016_0682_0 crossref_primary_10_1016_j_tet_2018_07_011 crossref_primary_10_1002_adsc_202001367 crossref_primary_10_1517_13543784_11_6_807 crossref_primary_10_1007_s11814_013_0044_5 crossref_primary_10_1016_j_tet_2023_133431 crossref_primary_10_2165_11317180_000000000_00000 crossref_primary_10_1016_j_tvjl_2007_03_026 crossref_primary_10_1016_j_mcat_2024_114257 crossref_primary_10_3810_pgm_2008_07_1797 crossref_primary_10_1016_j_mcat_2023_113404 crossref_primary_10_1021_jacs_3c00548 crossref_primary_10_1111_j_1365_4632_2004_02454_x crossref_primary_10_1111_j_1365_2133_2005_07049_x crossref_primary_10_1159_000351843 crossref_primary_10_1016_j_tetasy_2016_10_005 crossref_primary_10_1080_09546630601028745 crossref_primary_10_1002_cctc_201701601 crossref_primary_10_1007_s00253_020_10440_2 crossref_primary_10_1586_14737167_8_3_233 crossref_primary_10_1016_j_curtheres_2005_08_011 crossref_primary_10_1002_chem_201702509 crossref_primary_10_1517_14740338_2015_989831 crossref_primary_10_1046_j_1365_2125_2002_01611_x crossref_primary_10_1016_j_allerg_2003_11_005 crossref_primary_10_1111_j_1365_4632_2005_02609_x crossref_primary_10_2165_00044011_200222002_00001 crossref_primary_10_1016_j_tetasy_2017_10_007 crossref_primary_10_1185_030079904125003700 crossref_primary_10_1254_jphs_08037FP crossref_primary_10_1039_D0CC05003B crossref_primary_10_2165_00044011_200222002_00004 crossref_primary_10_1002_adsc_201500975 crossref_primary_10_1002_rcm_1983 crossref_primary_10_37667_pk_2001_280 crossref_primary_10_1038_sj_bjp_0707318 |
| Cites_doi | 10.1034/j.1398-9995.1999.00032.x 10.1046/j.1365-2222.1999.0290s3109.x 10.1111/j.1365-2222.1990.tb02456.x 10.1111/j.1365-2222.1989.tb02750.x 10.1016/S1081-1206(10)63462-X 10.2165/00003495-199040050-00009 10.2165/00003495-199346060-00008 10.1046/j.1365-2222.1999.0290s3125.x 10.1016/0091-6749(90)90091-H 10.1111/j.1398-9995.1997.tb00976.x 10.1097/00045391-199809000-00006 10.1016/S0091-6749(05)80100-9 10.1159/000211012 10.1183/09031936.93.05091137 10.1016/S0091-6749(05)80099-5 10.1136/bmj.316.7138.1147 10.1111/j.1365-2222.1990.tb02459.x 10.1007/BF01068419 10.1177/030006059101900213 |
| ContentType | Journal Article |
| Copyright | 2001 INIST-CNRS |
| Copyright_xml | – notice: 2001 INIST-CNRS |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 H94 |
| DOI | 10.1034/j.1398-9995.2001.00726.x |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1398-9995 |
| EndPage | 57 |
| ExternalDocumentID | 10_1034_j_1398_9995_2001_00726_x 11167352 855627 ALL726 |
| Genre | article Comparative Study Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 2WC 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB AOETA ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI TR2 UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 Y6R ZGI ZXP ZZTAW ~IA ~KM ~WT AAPBV AAVGM ABHUG ABPTK ACXME ADAWD ADDAD AFVGU AGJLS IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 H94 |
| ID | FETCH-LOGICAL-c4896-cd02e5163b217cfad9ae4530a1e772e9ece3a7b18b63fe3f9acf9ea66c21bfbd3 |
| IEDL.DBID | DR2 |
| ISSN | 0105-4538 |
| IngestDate | Fri Aug 16 09:32:26 EDT 2024 Fri Aug 23 09:38:14 EDT 2024 Sat Sep 28 08:40:55 EDT 2024 Sun Oct 22 16:09:31 EDT 2023 Sat Aug 24 00:57:49 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Human Immunopathology Skin disease Urticaria Antiasthma agent Cetirizine Antihistaminic Biological activity Chemotherapy Randomization Treatment Enantiomer Double blind study Antagonist H1 Histamine receptor Levocetirizine Comparative study |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4896-cd02e5163b217cfad9ae4530a1e772e9ece3a7b18b63fe3f9acf9ea66c21bfbd3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 11167352 |
| PQID | 17845948 |
| PQPubID | 23462 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_17845948 crossref_primary_10_1034_j_1398_9995_2001_00726_x pubmed_primary_11167352 pascalfrancis_primary_855627 wiley_primary_10_1034_j_1398_9995_2001_00726_x_ALL726 |
| PublicationCentury | 2000 |
| PublicationDate | January 2001 2001 2001-Jan 2001-01-00 20010101 |
| PublicationDateYYYYMMDD | 2001-01-01 |
| PublicationDate_xml | – month: 01 year: 2001 text: January 2001 |
| PublicationDecade | 2000 |
| PublicationPlace | Copenhagen |
| PublicationPlace_xml | – name: Copenhagen – name: Oxford – name: Denmark |
| PublicationTitle | Allergy (Copenhagen) |
| PublicationTitleAlternate | Allergy |
| PublicationYear | 2001 |
| Publisher | Munksgaard International Publishers Blackwell |
| Publisher_xml | – name: Munksgaard International Publishers – name: Blackwell |
| References | 1990; 40 1990; 86 1993; 46 1991; 19 1987; 135 1990; 20S 1990; 28 1997; 52 1999; 29 Suppl 3 1998; 316 1995 1999; 54 1993 1989; 26 1998; 5 1996; 76 1987; 59 1987; 15 1992; 5 Snyder SH (e_1_2_6_16_2) 1987; 59 e_1_2_6_18_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_11_2 e_1_2_6_17_2 e_1_2_6_14_2 e_1_2_6_15_2 e_1_2_6_20_2 White MV (e_1_2_6_10_2) 1987; 135 Bousquet J (e_1_2_6_7_2) 1992; 5 e_1_2_6_8_2 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_24_2 e_1_2_6_23_2 e_1_2_6_2_2 Steinijans VW (e_1_2_6_19_2) 1990; 28 e_1_2_6_22_2 e_1_2_6_21_2 e_1_2_6_26_2 e_1_2_6_25_2 |
| References_xml | – volume: 86 start-page: 360 year: 1990 end-page: 370 article-title: antigen‐induced cutaneous mediator release: simultaneous comparisons of histamine, tryptase and prostaglandin D release and the effect of oral corticosteroid administration publication-title: J Allergy Clin Immunol – volume: 316 start-page: 1147 year: 1998 end-page: 1150 article-title: Allergy and the skin. I. Urticaria publication-title: BMJ – volume: 135 start-page: 1165 year: 1987 end-page: 1176 article-title: Histamine and asthma publication-title: Am Rev Respir Dis – volume: 86 start-page: 371 year: 1990 end-page: 379 article-title: Determinants of histamine release in cutaneous allergic reactions in humans publication-title: J Allergy Clin Immunol – volume: 86 start-page: 540 year: 1990 end-page: 547 article-title: A double‐blind, single‐dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine‐induced wheals and flares during 24 hours in normal subjects publication-title: J Allergy Clin Immunol – volume: 59 start-page: 4 year: 1987 end-page: 8 article-title: Receptor effects of cetirizine publication-title: Ann Allergy – volume: 40 start-page: 762 year: 1990 end-page: 781 article-title: Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen‐induced asthma and chronic urticaria publication-title: Drugs – volume: 5 start-page: 1137 year: 1992 end-page: 1142 article-title: Antihistamines in the treatment of asthma publication-title: Eur Respir J – volume: 20S start-page: 3 year: 1990 end-page: 17 article-title: The pharmacology and mechanisms of action of histamine H ‐antagonists publication-title: Clin Exp Allergy – start-page: 22.1 year: 1995 end-page: 22.12 – volume: 52 start-page: 205 year: 1997 end-page: 209 article-title: Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis publication-title: Allergy – volume: 76 start-page: 448 year: 1996 end-page: 454 article-title: Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis publication-title: Ann Allergy Asthma Immunol – volume: 29 Suppl 3 start-page: 125 year: 1999 end-page: 132 article-title: Non‐cardiac adverse effects of antihistamines (H ‐receptor antagonists) publication-title: Clin Exp Allergy – volume: 28 start-page: 105 year: 1990 end-page: 110 article-title: Update on the statistical analysis of bioequivalence studies publication-title: Int J Clin Pharmacol – start-page: 255 year: 1993: end-page: 301. – volume: 26 start-page: 585 year: 1989 end-page: 589 article-title: Mediators and nasal allergy publication-title: Clin Exp Allergy – volume: 5 start-page: 21 year: 1992 end-page: 24 article-title: H antagonists in the management of the itch of urticarias publication-title: Skin Pharmacol – start-page: 21.1 year: 1995 end-page: 21.12 – volume: 29 Suppl 3 start-page: 109 year: 1999 end-page: 112 article-title: Assessment of urticaria and angio‐oedema publication-title: Clin Exp Allergy – volume: 15 start-page: 657 year: 1987 end-page: 680 article-title: A comparison of the two one‐sided tests procedure and power approach for assessing the bioequivalence of average bioavailability publication-title: J Pharmacokinet Biopharm – volume: 54 start-page: 700 year: 1999 end-page: 707 article-title: A double‐blind, single‐dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine, versus placebo: suppression of histamine‐induced wheal and flare response for 24 h in healthy male subjects publication-title: Allergy – volume: 5 start-page: 307 year: 1998 end-page: 311 article-title: Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis publication-title: Am J Ther – volume: 20S start-page: 31 year: 1990 end-page: 41 article-title: Histamine and asthma: an appraisal based on specific H ‐receptor antagonism publication-title: Clin Exp Allergy – volume: 19 start-page: 174 year: 1991 end-page: 179 article-title: Inhibitory effects of orally or sublingually administered cetirizine on histamine‐induced wheals, flares and their correlation with cetirizine plasma concentrations publication-title: J Int Med Res – volume: 46 start-page: 1055 year: 1993 end-page: 1080 article-title: Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders publication-title: Drugs – ident: e_1_2_6_20_2 doi: 10.1034/j.1398-9995.1999.00032.x – volume: 28 start-page: 105 year: 1990 ident: e_1_2_6_19_2 article-title: Update on the statistical analysis of bioequivalence studies publication-title: Int J Clin Pharmacol contributor: fullname: Steinijans VW – ident: e_1_2_6_2_2 doi: 10.1046/j.1365-2222.1999.0290s3109.x – ident: e_1_2_6_11_2 doi: 10.1111/j.1365-2222.1990.tb02456.x – ident: e_1_2_6_9_2 doi: 10.1111/j.1365-2222.1989.tb02750.x – ident: e_1_2_6_13_2 – ident: e_1_2_6_23_2 doi: 10.1016/S1081-1206(10)63462-X – ident: e_1_2_6_24_2 doi: 10.2165/00003495-199040050-00009 – ident: e_1_2_6_15_2 doi: 10.2165/00003495-199346060-00008 – ident: e_1_2_6_12_2 doi: 10.1046/j.1365-2222.1999.0290s3125.x – ident: e_1_2_6_21_2 doi: 10.1016/0091-6749(90)90091-H – ident: e_1_2_6_25_2 doi: 10.1111/j.1398-9995.1997.tb00976.x – ident: e_1_2_6_26_2 doi: 10.1097/00045391-199809000-00006 – ident: e_1_2_6_6_2 doi: 10.1016/S0091-6749(05)80100-9 – ident: e_1_2_6_14_2 doi: 10.1159/000211012 – volume: 5 start-page: 1137 year: 1992 ident: e_1_2_6_7_2 article-title: Antihistamines in the treatment of asthma publication-title: Eur Respir J doi: 10.1183/09031936.93.05091137 contributor: fullname: Bousquet J – volume: 135 start-page: 1165 year: 1987 ident: e_1_2_6_10_2 article-title: Histamine and asthma publication-title: Am Rev Respir Dis contributor: fullname: White MV – ident: e_1_2_6_5_2 doi: 10.1016/S0091-6749(05)80099-5 – ident: e_1_2_6_4_2 – volume: 59 start-page: 4 year: 1987 ident: e_1_2_6_16_2 article-title: Receptor effects of cetirizine publication-title: Ann Allergy contributor: fullname: Snyder SH – ident: e_1_2_6_3_2 doi: 10.1136/bmj.316.7138.1147 – ident: e_1_2_6_8_2 doi: 10.1111/j.1365-2222.1990.tb02459.x – ident: e_1_2_6_17_2 – ident: e_1_2_6_18_2 doi: 10.1007/BF01068419 – ident: e_1_2_6_22_2 doi: 10.1177/030006059101900213 |
| SSID | ssj0007290 |
| Score | 2.1100273 |
| Snippet | Background: Cetirizine is a highly efficacious and long‐acting second‐generation H1‐receptor antagonist for the treatment of allergic diseases, such as... Cetirizine is a highly efficacious and long-acting second-generation H1-receptor antagonist for the treatment of allergic diseases, such as allergic rhinitis... Background: Cetirizine is a highly efficacious and long‐acting second‐generation H 1 ‐receptor antagonist for the treatment of allergic diseases, such as... Cetirizine is a highly efficacious and long-acting second-generation H sub(1)-receptor antagonist for the treatment of allergic diseases, such as allergic... |
| SourceID | proquest crossref pubmed pascalfrancis wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 50 |
| SubjectTerms | Adolescent Adult Anti-Allergic Agents - adverse effects Anti-Allergic Agents - pharmacokinetics Anti-Allergic Agents - pharmacology antihistamines Biological and medical sciences cetirizine Cetirizine - adverse effects Cetirizine - pharmacokinetics Cetirizine - pharmacology Cross-Over Studies Double-Blind Method equivalence histamine Histamine - pharmacology Histamine and antagonists. Allergy Histamine H1 Antagonists - adverse effects Histamine H1 Antagonists - pharmacokinetics Histamine H1 Antagonists - pharmacology Humans levocetirizine Male Medical sciences Pharmacology. Drug treatments Skin Tests Stereoisomerism ucb 28557 urinary excretion urticaria |
| Title | A randomized, double‐blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine‐induced cutaneous responses in healthy adult volunteers |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1034%2Fj.1398-9995.2001.00726.x https://www.ncbi.nlm.nih.gov/pubmed/11167352 https://search.proquest.com/docview/17845948 |
| Volume | 56 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQDwgJ8f-TtoAPHJtlHcdOfFwhqgq1HBCVeov8M5FWbTfV7gZBTzxCX4PX4kk6Y2e3LAIJIaQcYsWexPaM_Tkef8PY6-As-NJWufZW5yWM69zZyubaFEH5sSyspIPCRx_0wXH5_kSdDP5PdBYm8UOsf7iRZcTxmgzcusVwTLxMRi4NGqsxipZ5IpJg6xHhSeLVI3z08YZJqhp-tyCcyEs08sGpB0W9-ZOgjZnq7oVdYKO1KdrF7-DoJrqN09P-fXa6qljySjkd9Us38pe_cD7-n5o_YPcGFMsnSe0eslswe8RuHw379I_Z9wnHKoTufHoJYY-Hrndn8OPblcOXYzpWmHxHuV-HQeQx7BH3sJzOp0R5vcfP4HP3cxol8t47XtRKVRyLEFmyPcdnKBoFo5YG7nuEu9D1Cz5P7r-w4FPMGv3cvvLIN8JpTEaNQuj7hB3vv_v09iAfgkLkvqyNzn0YF6AQRTpcTPnWBmMBO3RsBeBCAQx4kLZyonZatiBbY31rwGrtC-FaF-RTtjXrZvCccWeVNZTHIwpDCbXwVipXGBzGnJQiY2KlAM1F4v5o4p69LGnNhH3QUB9QJE_RxD5ovmRsd0NT1gWxZXRRZezVSnEatGPanElt0oiqLok6J2PPkj7dvJK2yhAnZ0xFrfjrb2kmh4d4s_2P5XbYneRwR9cu21rOe3iBCGzpXkbbugaH_imC |
| link.rule.ids | 315,786,790,1382,4043,27954,27955,27956,46327,46751 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLbQkAAJjX8IDOYLLpfSxLETX1aDqUC7C7RJu4ts50Sq1jVT2yC2Kx6B1-C1eJKdY6cdRSAhhNSLRo1Pavt8zmf7-DuMva6sAZeZPFbOqDiDfhFbk5tY6bSSri9SI-ig8PhQDY-zDyfypEsHRGdhgj7EesGNkOHHawI4LUh358SzgHKhEa1aS5rnJV4FW_WQUN5E9EtC6dtP11pSebfggoQizhDmXVgP2nrzJ0sb76q752aBzVaHfBe_I6Sb_Na_oA7usemqaiEu5bTXLm3PXf6i-vif6n6fbXdElg-C5z1gN2D2kN0ad1v1j9j3Acc6VM3Z5BKqPV41rZ3Cj6_fLD4dr32NKXyUu3UmRO4zH3EHy8l8QqrXe3wKn5ufr9Eib53laSFlzrEI6SWbM_wNTaNhdNSKuxYZLzTtgs9DBDAs-ARv9aFuF9xLjnAaltGpkP0-ZscH7472h3GXFyJ2WaFV7Kp-ChKJpMX5lKtNpQ1gj_ZNAjhXAA0OhMltUlglahC1Nq7WYJRyaWJrW4knbGvWzOAZ49ZIo-keh0QMLRSJM0LaVONIZoVIIpasPKA8D_Ifpd-2FxlNm7APSuoDSuaZlL4Pyi8R29lwlXVBbBmV5hHbXXlOiVCm_ZnQJmWSFxmp50TsaXCo60fSbhlS5YhJ7xZ__V_KwWiEX57_Y7lddnt4NB6Vo_eHH1-wOyH-jj47bGs5b-ElErKlfeWBdgUU8S2i |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQkSokBOWvBFrqA8dmWcexEx9XbVcFthVCVOot8s9EWrXdrHY3CHriEXgNXosnYWxntywCCSGkHBIlnsT2jP1NPP6GkJfOaLC5LlJptUxz6Jep0YVOpcqcsH2eae43Cp-cyuOz_M25OO_in_xemMgPsfrh5i0jjNfewKeu7raJ59HIuUJjVUp4N48FEmzZQzx5O5c8847Y4fsbKqmi-9-CeCLN0cq7qB6U9epPktamqrtTPcdWq2O6i9_h0XV4G-an4X1ysaxZDEu56LUL07PXv5A-_p-qb5F7HYylg6h3D8gtmDwkmyfdQv0j8m1AsQquuRpfg9unrmnNJXz_8tXgy_E6VNgHj1K7yoNIQ94jamExno095_U-vYSPzc_XKJG21tCsFKKgWMSzJesrvIeiUTCqqaO2RbwLTTunsxj_C3M6xkdDoNtnGghHqB-UUaUQ-z4mZ8OjDwfHaZcVIrV5qWRqXT8DgTDSoDdla-2UBuzQvmaAngIosMB1YVhpJK-B10rbWoGW0mbM1MbxJ2Rj0kzgKaFGC638MxZhGEoomdVcmEzhOGY4ZwlhSwWoppH8owqL9jz3ThP2QeX7wKfyZFXog-pTQnbWNGVVEFtGZkVC9paKU6Eh-9WZ2CYVK8rcc-ckZDvq080r_VoZAuWEiKAVf_0t1WA0wpNn_1huj2y-OxxWo9enb5-TOzH4zh87ZGMxa2EX0djCvAhm9gNrsCxR |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomized%2C+double-blind%2C+crossover+comparison+among+cetirizine%2C+levocetirizine%2C+and+ucb+28557+on+histamine-induced+cutaneous+responses+in+healthy+adult+volunteers&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=DEVALIA%2C+J.+L&rft.au=DE+VOS%2C+C&rft.au=HANOTTE%2C+F&rft.au=BALTES%2C+E&rft.date=2001&rft.pub=Blackwell&rft.issn=0105-4538&rft.eissn=1398-9995&rft.volume=56&rft.issue=1&rft.spage=50&rft.epage=57&rft_id=info:doi/10.1034%2Fj.1398-9995.2001.00726.x&rft.externalDBID=n%2Fa&rft.externalDocID=855627 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon |